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LETTERS TO THE EDITOR
“Care,” Cancer and Coenzyme Q10
I read, with great interest, the July 1998 article on the use of
Pravastatin in postmenopausal women with a history of
myocardial infarction, which revealed a significant reduction
in a wide range of cardiovascular events for those with
average cholesterol levels (1). These findings have been
significant enough to encourage the use of Pravastatin for
secondary prevention. However, I was alarmed by the
number of women in the treatment group who developed
breast cancer during the study period.
Although this phenomenon was attributed to chance by
the researchers, we have to pause in our enthusiasm to ask
ourselves a serious question: Could there possibly be any
relationship between the HMG-CoA-reductase inhibitors
and breast cancer? Does the fact that only one case of breast
cancer was found in the placebo group and 12 cases
developed in the experimental group represent a mere fluke
in research, or do we owe it to our female patients to look
further into the issue before it is dismissed? Although the
research authors state “there is no known biologic basis for
suspecting a causable link,” I suggest that there very well
may be. Some of the negative side effects already identified
with HMG-CoA-reductase inhibitors are reduction of se-
rum levels of Vitamin E, enhancing oxidizability (2) and
interfering with the endogenous synthesis of the important
nutrient/antioxidant CoEnzyme Q10 (Fig. 1).
Case study investigations that correlated a decrease in
CoEnzyme Q10 levels during Lovastatin administration in
humans (2,3) have been supported by subsequent double
blind placebo controlled research that also clearly demon-
strated scientific evidence of plasma CoQ10 lowering by
HMG-CoA-reductase inhibitors (4). Because we know that
HMG-CoA-reductase inhibitors are associated with lower
plasma levels of CoQ10, a second question arises: Could
there be any relationship between diminished CoQ10 and
cancer?
In a Swedish study of 116 cancer patients, a definite
relationship between low CoQ10 levels and the incidence of
breast cancer was identified. In fact, researchers reported a
38.5% incidence of breast cancer for those women with
plasma levels of CoQ10 levels below 0.6 mg/ml (0.6 to 0.8
is considered normal range) (5). The late Dr. Karl Folkers,
a chemist who won every scientific award short of the Nobel
Prize, spent his life investigating the chemistry of CoEn-
zyme Q10 (ubiquinone). He suggested that the impaired
biosynthesis of CoQ10 involved abnormal pairing of DNA
bases, which might suggest a rational basis for the molecular
causes of cancer (6).
In addition, early animal research has demonstrated
immune system decline in the presence of diminished levels
of CoQ10 (7). We also know that Q10 levels decline as a
factor of aging (8). The Pravastatin study, where the 12
cases were reported, included 576 postmenopausal women
who may have already been so compromised.
The fact that we have evidence that cancer is correlated
with lower Q10 levels and immune system dysfunction, and
that HMG-Co-A Reductase inhibitors disturb the produc-
tion of this essential nutrient and Vitamin E should be
enough to warrant further investigation to identify any
possible risks for postmenopausal women whose Q10 levels
are already depleted with age. Further research could more
clearly define assessment tools and treatment guidelines for
use of the “statin” drugs, such as the possible coadministra-
tion of Q10. One of the key goals of further research would
be to establish possible high risk groups when considering
HMG-CoA-reductase inhibitors, such as postmenopausal
women who are at known high risk for breast cancer.
We know that a woman’s risk of breast cancer increases
with positive family history, aging, high saturated fat diets,
excessive use of alcohol or repeated exposure to environ-
mental toxins such as pesticides or xenoestrogens. We need
to investigate if HMG-CoA-reductase inhibitors, such as
Pravastatin, may render these potentially high-risk subsets
of women even more vulnerable to the possibility of breast
cancer.
Certainly, the 46% risk reduction in coronary events is
compelling evidence for the use of Pravastatin. But we
cannot afford to ignore the 12 cases of breast cancer reported
in the experimental group of menopausal women. This
Figure 1. Biosynthetic Pathway of Cholesterol. The enzyme
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
is necessary for the conversion of HMG-CoA to mevalonic acid,
an early step in biosynthesis of cholesterol. Because mevalonic acid
is also a precursor of coenzyme Q10 via a branch of the cholesterol
biosynthetic pathway, HMG-CoA reductase inhibitors could re-
duce serum concentrations of coenzyme Q10. With Permission:
Sinatra ST. CoEnzyme Q10: A Vital Therapeutic Nutrient for the
Heart with Special Application in Congestive Heart Failure. Conn
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finding raises a red flag in my mind, suggesting the need for
further research, especially for women at risk of breast
cancer who are considered for or are already taking HMG-
CoA-reductase inhibitors for cholesterol-lowering. We owe
it to our patients to look further into this issue before we
routinely prescribe what has the potential to be a dangerous
medication for some women.
Stephen T. Sinatra, MD, FACC
Eastern Connecticut Health Network
University School of Medicine
Farmington, Connecticut
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REPLY
We looked very carefully into reasons for the difference in
the number of breast cancer cases between the pravastatin
and placebo groups in the CARE trial (1), and concluded
that it was a statistical aberration related to an unexpectedly
low incidence of new breast cancers in the placebo group.
There was not a single case of new invasive breast cancer
reported in the 290 women in the placebo group during the
five years of the trial; the one reported case was a metastasis
of a previously treated cancer. On the basis of epidemiolog-
ical data in the U.S. and Canada where the trial was
conducted, five cases of new invasive breast cancer were
expected (95% confidence interval, 0.6 to 9.3). In contrast,
the number of new invasive breast cancer cases in the
pravastatin group, eight, was closer to the expected number
of five, and within its confidence interval. These findings
strongly suggested that the imbalance in breast cancer
incidence between the treatment groups was linked to
chance rather than a biologic effect of pravastatin. This
conclusion was further supported by the findings from the
LIPID trial (2), which included more than 2.5 times as
many women as CARE, and had a longer median follow-up
(5.9 vs. 4.9 years). In LIPID, no differences were observed
between placebo and pravastatin-treated groups in the
incidence of breast cancer, with 10 reports in each group (2).
Findings were similar for long-term trials using other
HMG CoA reductase inhibitors (3,4).
One would have expected, if the coenzyme Q10 hypoth-
esis proposed by Dr. Sinatra was true, that increases in
incidence of other types of cancer would have been observed
with statin treatment. In fact, total cancer incidence was
similar in the drug and placebo groups not only in CARE,
but in all of the long-term statin trials, totaling over 30,000
patients (2–6).
Finally, there is no evidence that pravastatin produced
sustained decreases in plasma coenzyme Q10. In a study in
patients with hypercholesterolemia, pravastatin 40–80 mg
daily reduced coenzyme Q10 levels by 16 to 24% after four
and eight weeks of treatment, but levels returned to normal
by 20 weeks (12% above baseline) and remained normal
through to 56 weeks of treatment (13% above baseline).
The CARE trial showed that the benefits of pravastatin
treatment for women with coronary disease are substantial,
a 46% reduction in recurrent coronary events and a 56%
reduction in stroke. The lack of established risk of cancer or
other noncardiovascular morbidity clearly favors treating our
female coronary patients, a population in whom cardiovas-
cular disease is typically under-treated, despite being the
leading cause of death.
Frank M. Sacks, MD
Harvard School of Public Health and
Harvard Medical School
Boston, Massachusetts
Sandra J. Lewis, MD
Portland Cardiovascular Institute
Portland, Oregon
Hubert Pouleur, MD
Bristol Myers Squibb Pharmaceutical Research Institute
Princeton, New Jersey
Eugene Braunwald, MD
Brigham and Women’s Hospital and
Harvard Medical School
Boston, Massachusetts
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Aortic Atheromas and Historical Justice
We read with great interest the article by Dressler et al. (1)
dealing with the efficacy of anticoagulation and influence of
plaque morphology on recurrent stroke. Their findings are
in keeping with those of a recent report from our laboratory
stressing the importance of disrupted aortic plaques as a
major risk factor for systemic embolism in the elderly (2).
Moreover, the suggestion that anticoagulation should be the
treatment of choice in patients with mobile aortic athero-
mas—even in those with small mobile components—
represents a valuable contribution in the yet controversial
therapeutic approach to this challenging clinical problem.
We would like to bring to the authors’ attention two
points. First is an oversight in the Results section. When
describing the follow-up events of patients with atheroma,
readers are referred to Table 2, but this table deals only with
plaque dimensions (repeating data given in the text). The
next paragraph analyzes the influence of anticoagulation on
recurrent stroke in the three morphologic groups, and
readers are referred to Table 3, which actually deals with
follow-up events. We believe that these errors are probably
derived from a misprint that omitted the “true” Table 3,
data that would be interesting to see.
Second, it is stated at the beginning of the article that
“nearly 40 years have passed since the aorta was first
recognized as a source for systemic emboli,” quoting the
description by Winter of cerebral infarction caused by
atheromatous emboli (3). In fact, the entity had already
been described in the last century; experimental emboliza-
tion from aortic source was reported as early as in 1862 (4).
In addition, autopsy evidence of arterial occlusions by emboli
from eroded aortic atheromatous plaques was published in
1945 (5), twelve years before Winter’s communication. Today,
when the role of aortic atheromas in systemic emboli seems to
be obvious, historical justice requires that the pioneering works
of Panum and Flory should not be forgotten.
Enrique Z. Fisman, MD
Alexander Tenenbaum, MD, PhD
Cardiac Rehabilitation Institute
Chaim Sheba Medical Center
Tel-Aviv University
Tel-Aviv, Israel
REFERENCES
1. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile
aortic atheroma and systemic emboli: efficacy of anticoagulation
and influence of plaque morphology on recurrent stroke. J Am
Coll Cardiol 1998;31:134–8.
2. Tenenbaum A, Fisman EZ, Schneiderman J, et al. Disrupted
aortic plaques are a major risk factor for systemic embolism in
the elderly. Cardiology 1998;89:246–51.
3. Winter WJ Jr. Atheromatous emboli: a cause of cerebral
infarction. Arch Pathol Lab Med 1957;64:137–42.
4. Panum PL. Experimentelle beitrage zur lehre von der embolie.
Virchows Arch Pathol Physiol 1862;25:308–10.
5. Flory CM. Arterial occlusions by emboli from eroded aortic
atheromatous plaques. Am J Pathol 1945;21:549–65.
The Malpractice Crisis and
the “Expert” Witness:
The Problem and a Proposed Solution
Malpractice litigation in the U.S. has reached crisis. Premi-
ums for malpractice insurance are often astronomical, in
some cases forcing physicians out of practice, and the fear of
legal attack, often unjustified and even frivoulous, dogs
every practitioner. The entire structure of malpractice liti-
gation rests on expert testimony. Without expert testimony,
no malpractice action could ever succeed, and it comes as a
shock to realize that the malpractice crisis in the U.S. is only
made possible by certain physicians offering expert testi-
mony for large fees on either side of any case. These
individuals actually advertise their wares in legal journals,
sometimes as corporations of professional witnesses.
Knowledgeable attorneys are completely cynical about these
individuals: They know that they can hire a physician to
testify to “anything, absolutely anything”—to quote one of
the leading trial lawyers in the U.S.
There are remedies. Under British law, a witness, expert
or not, cannot be paid for testimony. Any evidence of
payment excludes the witness. (Under British law there are
no contingent fees for counsel, another wholesome provi-
sion.) My personal response is simple but effective and may
serve as a paradigm for the country. I offer my services, free
of charge, for any case within my competence. I review the
file, advise counsel and appear to testify if necessary. I am
careful to explain that I do this as a public service, with no
question of remuneration, as an obligation I feel I owe my
profession and the public. If there is evidence of gross
incompetence, I advise counsel to settle. If I see perjured
expert testimony, I am glad to take the stand to describe it
as such. This is well and good as far as it goes, but after some
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years of experience, I have learned two alarming facts. First,
conversations with jurors after a trial reveal that jurors accept
the testimony of professional witness without prejudice. The
fact that a physician makes a living testifying against other
physicians does not seem to disturb them. Second, the tech-
nicalities involved in many malpractice cases are light-years
outside the competence of the average jury: Lawyers and
professional witnesses are quick to take advantage of this fact.
Major legal reforms are urgent. The following steps are
logical and feasible: 1) The jury system should be excluded
in a professional liability hearing; 2) A judge should reach a
final verdict on the basis of expert testimony provided by
members of a panel of disinterested, objective, acknowledged
experts. A permanent panel of such experts should be main-
tained and the expert testimony should be provided gratis: At
most, the witness should be reimbursed for out-of-pocket
expenses. (The various specialty colleges could easily compile
such lists.); 3) The British system of loser-pays-all should be
adopted; and 4) The British system of absolutely excluding
testimony by a paid witness should be adopted.
Obviously, this solution will take time. In the interim, a
practicable palliative measure lies ready at hand. I urge my
colleagues to offer their services as I do, as an unpaid, impartial
expert, ready to review any case in my respective disciplines: If
they explain to the legal fraternity that they do this pro bono,
this simple measure will have a substantial influence.
As a first step, the several specialty colleges could compile
lists of volunteer impartial expert witnesses and provide
defendants with names in any given geographic locale when
a suit is filed. I find that a number of colleagues around the
country are doing exactly what I do, and we agree that the
work is not particularly onerous because it is possible to
review any hospital record and reach conclusions in about 30
minutes.
The malpractice crisis can be overcome by simple, fair-
minded measures. It is time for the several organized
specialty groups and organized medicine in general to take
appropriate steps.
Brendan P. Phibbs, MD
Padre Kino Hospital
Heart Station
2800 E. Ajo Way
Tucson, Arizona 85713
Reprint requests and correspondence: Dr. B. P. Phibbs, Padre
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The Influence of Age and
Gender On Heart Rate Variability (HRV)
The recent article of Umetani et al. (1) on the relation of
time domain heart rate variability (HRV) and heart rate
(HR) to age and gender presented much important infor-
mation. Nevertheless, there are serious inconsistencies in
their methodology and not all conclusions are substantiated
by their results. Although the authors acknowledge that it is
recognized that a (logarithmic) tranformation is necessary to
achieve a normal distribution of certain HRV indices, it is
not clear which tranformation, if any, was performed before
tests that require normally distributed variables, such as
Student t test or ANOVA, were used. A normal distribu-
tion, tested by e.g., the one sample Kolmogorov-Smirnov
test, can be obtained by a natural logarithmic transformation
for rMSSD and by calculating the square root for pNN50
(2). Furthermore, all age groups above 60 are substantially
underrepresented (e.g., only six men in the age category
80–99). Therefore, statements as “HRV . . . exhibits an
accelerated decline the . . . ninth and tenth decades” should
be interpreted with caution. Statistical analysis on a two-
decade basis to ensure an “adequate number” of subjects in
each group is an artifice that is not warranted because first,
a rapid evolution in autonomic modulation between the ages
of 10 and 30 can be expected, and second, the disappearance
of the gender difference is situated in the decade beyond age
40 (2), and not, as stated by the authors, between 50 and 69.
The authors report that the correlations of SD and
SDANN with age were lower than those of SDNN index,
rMSSD and pNN50. However, they fail to mention that
this can be attributed solely to an absence of any correlation
for SD and SDANN with age in female subjects. In Figure
3, correlation coefficients of r 5 –0.24 and –0.20 are
presented for women, which can be disregarded, because in
biomedical sciences, they indicate only little or no relation-
ship (3).
We disagree with the statement that the gender differ-
ences they observed could reflect lower levels of parasym-
pathetic activity in “young” female subjects and that this
view is supported by a higher HR in female subjects. This
may be true for teenagers, but not for adults (2). In their
two-decade age group 30–49 HR is still significantly higher
in women, and no significant difference in vagal indices is
detected. The suggestion that this may be related to a higher
level of sympathetic activity is not substantiated by the
results. SDNN index has not been accepted as a substitute
for heart rate spectral analysis (HRSA) low-frequency
power (4), the only available parameter that reflects pre-
dominantly sympathetic modulation (5) in physiological
conditions. HRSA was not performed in this study. The
higher HR in female patients can also be related to their
lower stroke volume. Furthermore, the reported gender
differences may derive from different central autonomic and
neurohumoral mechanisms in male and female patients
rather than solely from differences in autonomic outflow or
modulation.
No correction was made in the statistical analysis for
mean HR, a major determinant of HRV (6), and day/night
changes, that markedly affect autonomic modulation, were
not taken into account.
The reported results (1) complete previous reports on the
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effect of age and gender on time-domain HRV and HR, at
least in the young and middle-aged. If the authors had
included a sufficient number of participants (at least 20
healthy subjects per decade and per gender), this article
indeed could have delineated the effects of age and gender
on time-domain HRV and would have forwarded normal
ranges of HRV and HR over nine decades. Unfortunately,
only their most important study limitation can be empha-
sized: Additional larger studies that include the underrep-
resented groups are needed.
Dirk Ramaekers, MD
Hugo Ector, MD, PhD
Andre E. Aubert, PhD
Department of Cardiology
Gasthuisberg University Hospital
Leuven, Belgium
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REPLY
We appreciate the interest of Drs. Ramaekers, Ector, and
Aubert in our recent report on age and gender effects on
heart rate variability (HRV) and heart rate (HR) (1) and
have reexamined our data with respect to the questions
posed. Unfortunately, the authors did not provide a sum-
mary of their own data (2), on which they seem to largely
base their comments. This detracts from meaningful com-
parisons with their data.
Insofar as the questions posed are concerned, please
consider the following. A number of the issues also are
discussed in the limitations section of the article.
1. Raemakers et al. stated that statistical analysis should
have been preceded by a log transformation. We agree
that a transformation should be carried out in instances
where data are skewed. However, we compared limited
10 year age-range groups and found that data for 6 of the
8 age groups were normally distributed, even using the
pNN50 measure. Therefore, we felt justified in not
subjecting the data to log transformation before analysis.
2. We agree that the relatively small number of subjects in
the oldest age groups, particularly men over age 70,
represents a limitation of the study and that caution is
indicated in interpreting the decrease in HRV in this
group of subjects. However, to our best knowledge, this
is the largest published HRV data set to date for healthy
individuals over age 70. We are currently collecting data
from additional subjects over age 70, but it may be
difficult to achieve equal numbers of healthy older men
and women due to gender differences in mortality.
3. We agree with Raemakers et al. that a larger sample size
would be helpful in delineating the physiologic mecha-
nisms underlying age related gender HRV differences
and state this in our article. Larger sample size also
would permit a decade-by-decade analysis. Suggestions
that power spectrum analysis may be important with
respect to mechanistic determinations would be more
relevant if power spectral bands associated with sympa-
thetic activity were well defined.
More specifically, in our study, gender effects on HRV
were measure dependent. As shown in scatter plots of
HRV data from our total sample (Figure 2 B and C) (1)
HRV determined using rMSSD and pNN50 decreases
markedly with aging before age 50. Using these mea-
sures, HRV of young women is lower than that of age
matched men, with gender differences disappearing after
age 30. Parasympathetic modulation of heart rate (HR)
also decreases with aging (to age 30) (3). Using SDNN,
SDANN, and SDNN index measures, gender differences
disappear after age 50. Findings that HRV of women
determined using pNN50 and rMSSD, which reflect
parasympathetic activity, is lower than in age matched
men, suggest that gender HRV differences, at least
before age 30, may reflect differences in parasympathetic
modulation.
4. We agree that the lesser age dependence of SDNN and
SDANN measures may be largely due to the lesser age
dependence of SDNN and SDANN in females.
5. As mentioned by Ramaekers et al. (2) and others (4), HR
is a major determinant of HRV. Circadian changes also
represent an important consideration. However, in this
report, we did not consider these because it would have
made the report too long and complex. In addition, to
our best understanding, there are no established methods
for correcting HRV for mean HR. Tsuji et al. (4)
reported aging and HR effects on HRV separately.
In conclusion, we again thank Dr. Ramaekers and his
colleagues for their comments. However, we believe that
despite the limitations, our study has important implications
to our understanding HRV of normal individuals over the
life span and to the predictive use of HRV with respect to
mortality and cardiovascular morbidity, particularly in older
individuals.
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Cost-effectiveness of an Ineffective Therapy(?)
In the June issue of the Journal, Pedretti et al. (1) presented
an innovative study on the cost-effectiveness of different
tests to select postinfarct patients for amiodarone therapy.
However, as the accompanying editorial (2) pointed out, the
“cost-effectiveness of these tests can be no better than the
cost-effectiveness of the therapies prescribed based on their
results.” To this end, I think the conclusion reached in this
paper is weak and may be misleading for readers of this
journal.
Amiodarone has not been shown to improve overall
survival in post-MI patients. Only a meta-analysis (3),
which has important limitations, suggests a possible benefit.
The analyses in the present study relied entirely on the data
from EMIAT and CAMIAT trials, which did not show an
overall improvement in survival. No tests can be cost-
effective if the treatment selected is not. Using amiodarone
as a sole therapy in this high-risk group of patients,
especially those with a positive EP study, is clinically
unrealistic and renders the accompanying analyses irrele-
vant.
On the other hand, implantable defibrillators (ICDs)
have been shown to improve overall survival in two pub-
lished (MADIT and AVID) (4,5) and two unpublished
(CIDS and CASH) prospective randomized controlled
trials. Unfortunately, the use of ICDs as an alternative to
amiodarone was not emphasized by Pedretti et al. (1) or in
the accompanying editorial (2). Had the authors included
this proven therapy as a treatment option in their study,
invasive strategy with EP studies may turn out to be
cost-effective simply because of the effectiveness of ICD and
its superiority over amiodarone (4,5).
The conclusions reached by Pedretti et al. (1) at best
provide little clinically useful information and at worst are
potentially misleading. Because an inferior treatment was
chosen for analysis, it is not surprising that invasive electro-
physiology studies did not prove to be cost-effective. By
omitting to include ICDs as a treatment option and by
failing to discuss this important limitation, this study does
the readers of this journal a disservice by undermining the
true utility of electrophysiology studies in selecting patients
for appropriate treatment (4). I believe that the publication
of this paper, sets us back a full decade in our practice of
clinical electrophysiology.
James J. C. Ong, MD, FACC, FCCP
Tarzan, California
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REPLY
Dr Ong expressed some criticism concerning our recent
paper (1).
Results of base-case analysis showed that amiodarone
improved survival in recent post-MI patients with low heart
rate variability at an incremental cost between $20,000 and
$40,000/additional QALY which is consistent with other
currently founded programs, such as hemodialysis or treat-
ment of mild hypertension with diuretic drugs or propran-
olol. In our model, this acceptable incremental cost-
effectiveness ratio derived from a 17% amiodarone-induced
reduction in total mortality at two years, which is similar to
the significant survival benefit observed in a recent pub-
lished meta-analysis (2). Sensitivity analysis showed similar
cost-effectiveness ratios in other subgroups of patients
selected by different noninvasive testing, but not in those
with CAMIAT and EMIAT screening criteria. These data
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agree with CAMIAT and EMIAT findings, do not support
a systematic prophylactic use of amiodarone in post-MI
patients, but suggest a potential benefit for the drug at an
acceptable cost in different subgroups at high risk of
arrhythmias. To our knowledge, these findings provide
relevant, realistic and clinically useful information.
Asymptomatic patients who have positive noninvasive
and electrophysiologic testing after a recent MI are at very
high risk of arrhythmic death, with a relatively low risk of
nonsudden death. It is in these patients that an antiarrhyth-
mic intervention has the greatest potential to improve
outcome and amiodarone is an effective antiarrhythmic drug
because it reduced arrhythmic mortality between 33% and
45% in CAMIAT and EMIAT trials. Thus, it is relevant,
realistic and clinically useful to compare the “two-level” with
the more simple noninvasive approach in terms of cost-
effectiveness ratio in this therapeutic scenario. Obviously,
such an analysis is appropriate also with the ICD as a
therapy, and would be very intriguing because ability of the
ICD to abort sudden death is no longer in question.
Unfortunately, it is impossible to provide good answers to
multiple questions in a single study. Moreover, all available
data about ICD effectiveness are relative to patients with
late post-MI or who suffered from symptomatic ventricular
tachycardia or were resuscitated from cardiac arrest (3).
These findings may not be a priori extended to recent
post-MI asymptomatic patients, like those included in our
model. Some ICD studies ongoing or recently started will
provide in the next few years a definitive answer about the
capability of the ICD in improving overall survival in recent
post-MI patients.
Roberto F. E. Pedretti, MD, FESC
Fondazione Salvatore Maugeri, Care and Research Institute
Division of Cardiology, Rehabilitation Institute
Via Roncaccio, 16, I-21049, Tradate (VA), Italy
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